Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Gyre Therapeutics (GYRE) Non-Current Receivables (2023 - 2024)

Gyre Therapeutics (GYRE) has disclosed Non-Current Receivables for 2 consecutive years, with $4.9 million as the latest value for Q3 2024.

  • On a quarterly basis, Non-Current Receivables rose 5.06% to $4.9 million in Q3 2024 year-over-year; TTM through Sep 2024 was $4.9 million, a 5.06% increase, with the full-year FY2023 number at $4.7 million, changed N/A from a year prior.
  • Non-Current Receivables was $4.9 million for Q3 2024 at Gyre Therapeutics, up from $4.8 million in the prior quarter.
  • In the past five years, Non-Current Receivables ranged from a high of $4.9 million in Q3 2024 to a low of $4.6 million in Q1 2023.